Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.

Indeed, in this patients’ subgroup, the tucatinib-based combination yielded highly significant and clinically meaningful benefit, both intracranially and extracranially, thus being suggested as a potential preferred second-line option over T-DXd in patients with active brain metastases progressing to first-line dual-HER2 blockade. 82 However, this near-future scenario may be an object of intense debate pending the results from the phase II—Simon’s two stage—TUXEDO-1 trial, assessing T-DXd in HER2+ MBC patients, priorly exposed to trastuzumab and pertuzumab, with newly diagnosed brain metastases or brain lesions radiologically progressing after prior local therapy.

also in 132,142 other papers